Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors

URN to cite this document:: urn:nbn:de:bvb:355-epub-543395
DOI to cite this document:: 10.5283/epub.54339

Oppolzer, Immanuel Augustin ; Riester, Josef ; Büttner, Roland ; Burger, Maximilian ; Schnabel, Marco Julius

License: Creative Commons Attribution 4.0
PDF - Published Version
(522kB)

Date of publication of this fulltext: 09 Jun 2023 05:57

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Export bibliographical data

Abstract

Purpose To evaluate the incidence, diagnosis and treatment of immune-related adverse events (e-irAE) of checkpoint inhibition (ICI) in metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC). Methods A retrospective, single-center study was conducted to identify a cohort that received ICI for mUC or mRCC. e-irAE were classified according to the CTCAE V.5.0. Patients ...